Independent Dose–Response Associations between Fetuin-A and Lean Nonalcoholic Fatty Liver Disease

Lu, Chia‐Wen; Lee, Yi Chen; Chiang, Chien-Hsieh; Chang, Hao; Yang, Wei–Shiung; Huang, Kuo‐Chin

doi:10.3390/nu13092928

Cited by 8 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fetuin-A has been widely studied in a variety of diseases including non-alcoholic fatty liver disease (23), diabetes (24), cardiovascular disease (25), sepsis (17, 18), periodontitis (26,27), osteoarthritis (28), chronic kidney disease (29), inflammatory bowel disease (30), and encapsulating peritoneal sclerosis (31). Many of these diseases are associated with inflammation.…”

Section: Discussionmentioning

confidence: 99%

Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study

Zhao

Shang²,

Luo³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundCommunity-acquired pneumonia (CAP) is a respiratory disease that frequently requires hospital admission, and is a significant cause of death worldwide. Plasma fetuin-A levels were significantly lower in patients with sepsis, but data regarding CAP are scarce. This study aimed to evaluate the usefulness of fetuin-A as a prognostic biomarker of CAP.MethodsA multicenter cohort study on CAP was conducted between January 2017 and December 2018. Demographic and clinical data were recorded for all enrolled patients. Plasma fetuin-A levels were determined using a quantitative enzyme-linked immunosorbent assay. A Cox proportional hazards regression analysis was used to analyse the effect of variables on 30-day mortality. A logistic regression analysis was performed to assess risk factors associated with severe CAP (SCAP) and 30-day mortality. A receiver operating characteristic (ROC) curve was used to verify the association between variables and CAP prognosis. Correlations were assessed using Spearman's test. Survival curves were constructed and compared using the log-rank test.ResultsA total of 283 patients with CAP were enrolled in this study. Fetuin-A levels were decreased in patients with CAP, especially in SCAP and non-survivors. A cox regression analysis showed that CURB-65 and fetuin-A levels were independent prognostic indicators of 30-day mortality. Via a multiple logistic regression analysis, plasma level of fetuin-A (<202.86 mg/L) was determined to be the strongest independent predictor of 30-day mortality considered (odds ratio, 57.365), and also was also determined to be an independent predictor of SCAP. The area under the curve (AUC) of fetuin-A for predicting 30-day mortality was 0.871, and accuracy was high (P < 0.05). Plasma fetuin-A levels were negatively correlated with WBC, NE%, Glu, CRP, PCT, CURB-65, and pneumonia severity index scores and positively correlated with albumin level. Kaplan–Meier curves showed that lower plasma levels of fetuin-A levels were associated with increased 30-day mortality levels (P < 0.0001).ConclusionPlasma fetuin-A levels were decreased in patients with CAP. Fetuin-A can reliably predict mortality in patients with CAP, and is a useful diagnostic indicator of SCAP.

show abstract

Section: Discussionmentioning

confidence: 99%

Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study

Zhao

Shang²,

Luo³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Fetuin-A levels in NAFLD patients do not vary even with different diagnostic methods. [28][29] [30] The lowest average NFS value in the NAFLD group degree I was -1,87 (-2,67 to -0,85). Then the NFS average at NAFLD degree II was -0,85 (-1,96 to 0,38).…”

Section: Discussionmentioning

confidence: 99%

The Correlation between Fetuin-A Levels And Nafld Fibrosis Score (NFS)

Hafiz Syaifullah Siregar

2022

Sumat. Med. J.

View full text Add to dashboard Cite

Abstract. Fetuin-A is a plasma glycoprotein expressed in the liver. Fatty liver accumulation because changing fetuin-A expression leads to nonalcoholic fatty liver disease (NAFLD). The benefits of serum fetuin-A as a predictor of fibrosis biomarkers in NAFLD patients remain unclear. Non-invasive scoring system predicting fibrosis among patients with NAFLD is the NAFLD fibrosis score (NFS). Objective. This study aims to find the correlation between circulating fetuin-A levels and NFS in NAFLD patients. Methods. Eighty subjects (male, 52; female, 26) followed this cross-sectional study. NAFLD is diagnosed with an abdominal ultrasound. The serum levels of fetuin-A measured by ELISA. NFS is used to identify the probability of fibrosis in subjects. The correlation between Fetuin-A levels and NFS was determined using Pearson correlation tests. A p-value < 0.05 was significant. Results. There was significant difference in fetuin-A levels (p < 0.001) between NAFLD degree I (421.71 pg/mL), NAFLD degree II (494.88 pg/mL), and NAFLD degree III (692 pg/mL). The NFS low probability score in 46 subjects and NFS indeterminate score in 34 subjects. Serum concentrations of fetuin-A correlate significantly with NFS (r = 0.478, p < 0.001). Conclusion. There is a positive correlation between serum levels of fetuin-A and NFS.

show abstract

“…The combination of serum markers and other indicators is valuable for screening diseases due to their convenience, low cost and accurate diagnosis. Insulin resistance (IR) is involved in the pathogenesis and progression of lean NAFLD ( 8 ). Homeostatic model assessment for IR (HOMA-IR) is widely utilized in IR-related disorders and is the gold standard for diagnosing lean NAFLD ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

Association between TyG index trajectory and new-onset lean NAFLD: a longitudinal study

Liu,

Chen,

Qin

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectiveThe purpose of this manuscript is to identify longitudinal trajectories of changes in triglyceride glucose (TyG) index and investigate the association of TyG index trajectories with risk of lean nonalcoholic fatty liver disease (NAFLD).MethodsUsing data from 1,109 participants in the Health Management Cohort longitudinal study, we used Latent Class Growth Modeling (LCGM) to develop TyG index trajectories. Using a Cox proportional hazard model, the relationship between TyG index trajectories and incident lean NAFLD was analyzed. Restricted cubic splines (RCS) were used to visually display the dose-response association between TyG index and lean NAFLD. We also deployed machine learning (ML) via Light Gradient Boosting Machine (LightGBM) to predict lean NAFLD, validated by receiver operating characteristic curves (ROCs). The LightGBM model was used to create an online tool for medical use. In addition, NAFLD was assessed by abdominal ultrasound after excluding other liver fat causes.ResultsThe median age of the population was 46.6 years, and 440 (39.68%) of the participants were men. Three distinct TyG index trajectories were identified: “low stable” (TyG index ranged from 7.66 to 7.71, n=206, 18.5%), “moderate stable” (TyG index ranged from 8.11 to 8.15, n=542, 48.8%), and “high stable” (TyG index ranged from 8.61 to 8.67, n=363, 32.7%). Using a “low stable” trajectory as a reference, a “high stable” trajectory was associated with an increased risk of lean-NAFLD (HR: 2.668, 95% CI: 1.098-6.484). After adjusting for baseline age, WC, SBP, BMI, and ALT, HR increased slightly in “moderate stable” and “high stable” trajectories to 1.767 (95% CI:0.730-4.275) and 2.668 (95% CI:1.098-6.484), respectively. RCS analysis showed a significant nonlinear dose-response relationship between TyG index and lean NAFLD risk (χ2 = 11.5, P=0.003). The LightGBM model demonstrated high accuracy (Train AUC 0.870, Test AUC 0.766). An online tool based on our model was developed to assist clinicians in assessing lean NAFLD risk.ConclusionThe TyG index serves as a promising noninvasive marker for lean NAFLD, with significant implications for clinical practice and public health policy.

show abstract

Independent Dose–Response Associations between Fetuin-A and Lean Nonalcoholic Fatty Liver Disease

Cited by 8 publications

References 43 publications

Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study

Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study

The Correlation between Fetuin-A Levels And Nafld Fibrosis Score (NFS)

Association between TyG index trajectory and new-onset lean NAFLD: a longitudinal study

Contact Info

Product

Resources

About